Nouscom Raises €120 Million in Series D Funding to Advance Cancer Immunotherapy

The funding round was co-led by M Ventures and Revelation Partners. New investors included Angelini Ventures, the European Investment Bank (EIB), and Neva SGR, part of Intesa Sanpaolo Group.

Several existing investors also participated in the round, including 5AM Ventures, Andera Partners, Bpifrance, CDP Venture Capital, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, and XGEN Ventures. The funding will support the development of Nouscom's experimental, ready-to-use cancer immunotherapy based on neoantigens.

“Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery“, says Marina Udier, Ph.D., Chief Executive Officer of Nouscom. “We built Nouscom to change that equation. This financing, alongside the data we are presenting at ESMO, puts us closer to a world where cancer is stopped before it starts. I am grateful to our new and existing investors for backing that conviction, and to the team behind NOUS-209.”

“This significant financing reflects the confidence of our investors in Nouscom’s vision, team and the transformative potential of cancer interception,” said Göran Ando, M.D., Independent Chair of the Board of Nouscom. “With this backing, we are well positioned to accelerate NOUS-209’s clinical development and our commitment to those living with Lynch Syndrome. I am delighted to welcome our new investors, whose support further strengthens Nouscom as we enter this next chapter.”

Dr. Hakan Goker, Managing Director and Head of Biotechnology Investments at M Ventures, says: “What sets Nouscom apart is its unique cancer interception approach and the platform that enables it. Maturing clinical evidence and a regulatory-aligned path into a registration-enabling trial in such an unchartered space is a rare combination for a private biotech company and the commitment of the investor syndicate underpins this deep conviction.”

Founded in 2015, Nouscom is a biotech company developing new cancer treatments that help the immune system recognise and fight cancer. Its research focuses on treating cancer at different stages, from preventing its development in high-risk patients to treating advanced cancer that has spread to other parts of the body.

The company uses its own viral vector technology to deliver specially designed neoantigens, which help train the immune system to identify and attack cancer cells.

Nouscom’s main programme, NOUS-209, is an off-the-shelf immunotherapy being tested in clinical trials. It is being developed to help prevent certain cancers in people with Lynch syndrome (LS) and treat metastatic colorectal cancer (MSI mCRC). The company is also developing NOUS-PEV, a personalised cancer immunotherapy that has completed a Phase 1b clinical trial, with results published.

Read Also- Vessla Raises €2.94 Million in Pre-Seed Funding to Build AI Operating System for Real Estate